Cargando…
Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality
We describe the epidemiology of C. difficile infections (CDIs) focused on treatment and analyze the risk factors for mortality. This is a retrospective cohort study of CDI cases with a positive A/B toxin in the stool in 2017–2018. We analyzed the demographic data, comorbidities, previous use of anti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495058/ https://www.ncbi.nlm.nih.gov/pubmed/36139942 http://dx.doi.org/10.3390/antibiotics11091162 |
_version_ | 1784793930710122496 |
---|---|
author | Alves, Joana Darc Freitas Yamaguti, Augusto de Mendonça, João Silva de Melo Gamba, Cristiano Fonseca, Cibele Lefreve Paraskevopoulos, Daniela K. S. de Paula, Alexandre Inacio Hosino, Nair Costa, Silvia Figueiredo Guimarães, Thaís |
author_facet | Alves, Joana Darc Freitas Yamaguti, Augusto de Mendonça, João Silva de Melo Gamba, Cristiano Fonseca, Cibele Lefreve Paraskevopoulos, Daniela K. S. de Paula, Alexandre Inacio Hosino, Nair Costa, Silvia Figueiredo Guimarães, Thaís |
author_sort | Alves, Joana Darc Freitas |
collection | PubMed |
description | We describe the epidemiology of C. difficile infections (CDIs) focused on treatment and analyze the risk factors for mortality. This is a retrospective cohort study of CDI cases with a positive A/B toxin in the stool in 2017–2018. We analyzed the demographic data, comorbidities, previous use of antimicrobials, severity, and treatment, and we performed multivariate analysis to predict the 30-days mortality. We analyzed 84 patients, 37 (44%) of which were male, where the mean age was 68.1 years and 83 (99%) had comorbidities. The percentage of positivity of the A/B toxin was 11.6%, and the overall incidence density was 1.78/10,000 patient days. Among the patients, 65.4% had previous use of antimicrobials, with third-generation cephalosporins being the class most prescribed, and 22.6% of cases were severe. Treatment was prescribed for 70 (83.3%) patients, and there was no statistically significant difference between the initial treatment with metronidazole and vancomycin even in severe cases. The 30-day mortality was 7/84 (8.3%), and the risk factors associated with mortality was a severity score ≥2 (OR: 6.0; CI: 1.15–31.1; p = 0.03). In this cohort of CDI-affected patients with comorbidities and cancer, metronidazole was shown to be a good option for treating CDIs, and the severity score was the only independent risk factor for death. |
format | Online Article Text |
id | pubmed-9495058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94950582022-09-23 Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality Alves, Joana Darc Freitas Yamaguti, Augusto de Mendonça, João Silva de Melo Gamba, Cristiano Fonseca, Cibele Lefreve Paraskevopoulos, Daniela K. S. de Paula, Alexandre Inacio Hosino, Nair Costa, Silvia Figueiredo Guimarães, Thaís Antibiotics (Basel) Article We describe the epidemiology of C. difficile infections (CDIs) focused on treatment and analyze the risk factors for mortality. This is a retrospective cohort study of CDI cases with a positive A/B toxin in the stool in 2017–2018. We analyzed the demographic data, comorbidities, previous use of antimicrobials, severity, and treatment, and we performed multivariate analysis to predict the 30-days mortality. We analyzed 84 patients, 37 (44%) of which were male, where the mean age was 68.1 years and 83 (99%) had comorbidities. The percentage of positivity of the A/B toxin was 11.6%, and the overall incidence density was 1.78/10,000 patient days. Among the patients, 65.4% had previous use of antimicrobials, with third-generation cephalosporins being the class most prescribed, and 22.6% of cases were severe. Treatment was prescribed for 70 (83.3%) patients, and there was no statistically significant difference between the initial treatment with metronidazole and vancomycin even in severe cases. The 30-day mortality was 7/84 (8.3%), and the risk factors associated with mortality was a severity score ≥2 (OR: 6.0; CI: 1.15–31.1; p = 0.03). In this cohort of CDI-affected patients with comorbidities and cancer, metronidazole was shown to be a good option for treating CDIs, and the severity score was the only independent risk factor for death. MDPI 2022-08-28 /pmc/articles/PMC9495058/ /pubmed/36139942 http://dx.doi.org/10.3390/antibiotics11091162 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alves, Joana Darc Freitas Yamaguti, Augusto de Mendonça, João Silva de Melo Gamba, Cristiano Fonseca, Cibele Lefreve Paraskevopoulos, Daniela K. S. de Paula, Alexandre Inacio Hosino, Nair Costa, Silvia Figueiredo Guimarães, Thaís Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality |
title | Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality |
title_full | Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality |
title_fullStr | Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality |
title_full_unstemmed | Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality |
title_short | Metronidazole for Treatment of Clostridioides difficile Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality |
title_sort | metronidazole for treatment of clostridioides difficile infections in brazil: a single-center experience and risk factors for mortality |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495058/ https://www.ncbi.nlm.nih.gov/pubmed/36139942 http://dx.doi.org/10.3390/antibiotics11091162 |
work_keys_str_mv | AT alvesjoanadarcfreitas metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT yamagutiaugusto metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT demendoncajoaosilva metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT demelogambacristiano metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT fonsecacibelelefreve metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT paraskevopoulosdanielaks metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT depaulaalexandreinacio metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT hosinonair metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT costasilviafigueiredo metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality AT guimaraesthais metronidazolefortreatmentofclostridioidesdifficileinfectionsinbrazilasinglecenterexperienceandriskfactorsformortality |